MarPipe · Project

Marine Organisms as a Source of New Antibiotic and Anticancer Drug Candidates

healthPrototypeTRL 3Thin data (2/5)

The ocean is full of tiny organisms that produce powerful chemical compounds — some of which could become the next generation of antibiotics or cancer drugs. MarPipe trained 11 PhD researchers to find these compounds from marine microbes, including samples collected from 5000 meters deep in the sub-Antarctic. Think of it as a talent pipeline combined with a drug discovery pipeline: young scientists learned every step from fishing out new microbes to testing promising molecules before they reach clinical trials. The long-term goal was even to spin out a marine biodiscovery startup company from the consortium.

By the numbers

PhD researchers trained across the full marine drug discovery pipeline

consortium partners collaborating on marine biodiscovery

countries represented in the research network

5000m

depth of deep-sea samples collected from the sub-Antarctic

SMEs involved in the consortium

industry partners in the training network

The business problem

What needed solving

Antibiotic resistance is rising and cancer treatment options remain limited, yet the pharmaceutical pipeline for new antimicrobial and anticancer drugs is running dry. Marine organisms represent an enormous untapped reservoir of bioactive compounds, but the field suffers from bottlenecks: low compound yields, re-discovery of known molecules, and toxicity issues that stall development. Companies need access to fresh compound libraries and trained scientists who can navigate the entire marine biodiscovery pipeline efficiently.

The solution

What was built

MarPipe trained 11 PhD researchers across all phases of the marine drug discovery pipeline — from isolating new microbial strains (including from 5000m deep-sea samples) through mass spectrometry analysis to pre-clinical development of antimicrobial and anticancer lead compounds. The project also produced 15 deliverables including a project website, and aimed to establish a marine biodiscovery startup company.

Audience

Who needs this

Biotech companies with antimicrobial or oncology pipelines seeking new compound leadsMarine biotechnology firms commercializing ocean-derived natural productsContract research organizations offering natural product screening servicesPharmaceutical companies scouting for early-stage antimicrobial candidates against resistant pathogensCosmetics or nutraceutical companies interested in marine bioactive ingredients

Business applications

Who can put this to work

Pharmaceutical & Biotech

SME

Target: Small to mid-size biotech companies developing anti-infective or oncology pipelines

If you are a biotech company struggling with a dry antimicrobial or anticancer pipeline — MarPipe developed lead compounds from marine microorganisms through a full biodiscovery pipeline, from strain isolation to pre-clinical development. The project built on results from a prior EU project (PharmaSea), advancing compounds further toward drug candidacy. With 11 PhD projects covering every stage, the consortium generated new know-how on overcoming low yields and compound toxicity.

Marine Biotechnology

SME

Target: Companies commercializing marine-derived natural products (cosmetics, nutraceuticals, bio-materials)

If you are a marine biotech company looking for new bioactive molecules beyond your current library — MarPipe explored deep-sea samples from 5000m depth in the sub-Antarctic, a largely untapped source of chemodiversity. The consortium of 14 partners across 8 countries built expertise in isolating novel microbial strains and screening them for biological activity. Their methods for overcoming known bottlenecks like re-isolation of known compounds could directly improve your discovery hit rates.

Contract Research & Drug Discovery Services

any

Target: CROs offering natural product screening or marine compound libraries

If you are a contract research organization that offers natural product screening services — MarPipe trained 11 early-stage researchers across the entire marine drug discovery pipeline, from microbial strain isolation through mass spectrometry analysis to pre-clinical compound development. The consortium included 3 SMEs and 4 industry partners actively involved in biodiscovery. Access to their methods, compound libraries, or trained talent could expand your marine natural products service offering.

Frequently asked

Quick answers

What would it cost to access MarPipe's compounds or screening results?

MarPipe was a training network (MSCA-ITN), not a product development project, so there is no off-the-shelf pricing. Any licensing of lead compounds or access to strain libraries would need to be negotiated directly with the coordinator (CNR, Italy) and relevant consortium partners. Costs would depend on the stage of development and exclusivity terms.

Can these marine compounds be produced at industrial scale?

Based on available project data, one of the key bottlenecks MarPipe aimed to address was low yields of bioactive compounds. The project focused on pre-clinical development stages, meaning industrial-scale production was not yet demonstrated. Scaling marine natural products typically requires fermentation optimization or synthetic biology approaches that would come after this project's scope.

What is the IP situation — can I license any of this?

The consortium of 14 partners across 8 countries includes both academic and industrial partners. IP generated by MSCA training networks is typically owned by the host institutions of the individual researchers. You would need to contact CNR (the coordinator) to understand which results are available for licensing and under what terms.

How close are these compounds to becoming actual drugs?

MarPipe covered stages up to pre-clinical development of lead compounds, which in drug discovery terms means the molecules showed promising activity in lab tests but have not entered human clinical trials. This places the results in early drug discovery — typically years away from market. The project built on earlier results from the PharmaSea project, so some compound families may be more advanced.

What specific diseases or infections were targeted?

The project focused on two therapeutic areas: antimicrobial compounds (addressing antibiotic resistance) and anticancer compounds. Based on available project data, specific pathogen or cancer targets for individual lead compounds are not detailed in the objective, but the broad focus on antimicrobials is directly relevant to the global AMR crisis.

Is the planned marine biodiscovery startup company operational?

The objective mentions the creation of a marine biodiscovery startup as a final outcome. Based on available project data, it is not confirmed whether this startup was formally established after the project ended in April 2021. This would need to be verified with the coordinator.

Consortium

Who built it

MarPipe's consortium of 14 partners across 8 countries (Italy, Norway, UK, Germany, Belgium, Ireland, Spain, Netherlands) is well-balanced for a training network: 5 universities, 5 research organizations, and 4 industry partners including 3 SMEs. The 29% industry ratio is notable for a training program — it means PhD researchers got genuine exposure to commercial biodiscovery operations, not just academic labs. The coordinator is CNR (Italy's National Research Council), one of Europe's largest public research bodies, which gives the network institutional weight. The involvement of companies like eCOAST, MEDINA, MicroDish, and Italbiotec signals that there is commercial interest in marine natural products, though the primary output remains trained talent and early-stage research rather than market-ready products.

CONSIGLIO NAZIONALE DELLE RICERCHECoordinator · IT
UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITETparticipant · NO
THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEENparticipant · UK
CONSORZIO ITALBIOTECparticipant · IT
ABS-INTERNATIONALparticipant · BE
STAZIONE ZOOLOGICA ANTON DOHRNparticipant · IT
FUNDACION CENTRO DE EXCELENCIA EN INVESTIGACION DE MEDICAMENTOS INNOVADORES EN ANDALUCIAparticipant · ES
ECOASTparticipant · BE
ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLUpartner · IT
WAGENINGEN UNIVERSITYparticipant · NL
HELMHOLTZ-ZENTRUM FUR OZEANFORSCHUNG KIEL (GEOMAR)participant · DE
KATHOLIEKE UNIVERSITEIT LEUVENparticipant · BE
UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORKparticipant · IE

How to reach the team

Consiglio Nazionale delle Ricerche (CNR), Italy — reach out via their institutional channels or the project website

Order a report on this consortium See CONSIGLIO NAZIONALE DELLE RICERCHE profile →

Next steps

Talk to the team behind this work.

Want to explore marine-derived compound opportunities from MarPipe or similar EU biodiscovery projects? SciTransfer can connect you with the right research team. Contact us for a tailored brief.

Order a report on this topic More in Health & Biomedical